Hemostasis alterations in metabolic syndrome (Review)

International Journal of Molecular Medicine

Volumn 18, Issue 5, 2006, Pages 969-974

  Palomo, Iván ^a   Alarcón, Marcelo ^a   Moore Carrasco, Rodrigo ^a   Argilés, Josep M ^b  

^a UNIVERSIDAD DE TALCA   (Chile)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hemostasis; Metabolic syndrome; Thrombosis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; METABOLIC SYNDROME X; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HEMOSTASIS; HUMANS; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 37349053532     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.5.969     Document Type: Review

References (104)

1. Anuario Estadistico, Dirección del Servicio de Salud del Maule.
2. Instituto nacional de Estadística. Anuario de Demografía 2000. INE, Chile, 2000.
3. Alexander CM, Landsman PB, Teutsch SM and Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52: 1210-1214, 2003.
4. Hulthe J, Bokemark L, Wikstrand J and Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20: 2140-2147, 2000.
5. Sakkinen PA, Wahl P, Cushman M, Lewis MR and Tracy RP: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152: 897-907, 2000.
6. Juhan-Vague I, Alessi MC and Vague P: Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34: 457-462, 1991.
7. Fletcher B and Lamendola C: Insulin resistance syndrome. J Cardiovasc Nurs 19: 339-345, 2004.
8. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421, 2002.
9. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
10. Liese AD, Mayer-Davis EJ and Haffner SM: Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 20: 157-172, 1998.
11. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB and Wilson PW: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283: 221-228, 2000.
12. Ford ES, Giles WH and Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359, 2002.
13. Grundy SM: Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105: 2696-2698, 2002.
14. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P and Yusuf S: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108: 420-425, 2003.
15. Trayhurn P and Beattie JH: Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60: 329-339, 2001.
16. Beltowski J: Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit 9: RA55-RA61, 2003.
17. Baumgartner-Parzer SM and Waldhausl WK: The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Exp Clin Endocrinol Diabetes 109 (suppl 2): S166-S179, 2001.
18. Bonetti PO, Lerman LO and Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175, 2003.
19. Mather KJ, Verma S and Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 37: 1344-1350, 2001.
20. Verma S and Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation 105: 546-549, 2002. (Pubitemid 34123425)
21. Kharbanda RK and Deanfield JE: Functions of the healthy endothelium. Coron Artery Dis 12: 485-491, 2001.
22. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T and Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102: 1296-1301, 2000.
23. Ferroni P, Basili S, Falco A and Davi G: Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 6: 424-431, 2004.
24. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M and Rimm EB: Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157: 495-503, 2001.
25. Yudkin JS, Stehouwer CD, Emeis JJ and Coppack SW: Creactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972-978, 1999.
26. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
27. Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
28. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW and Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107: 1255-1262, 2001.
29. Kuryliszyn-Moskal A, Klimiuk PA and Sierakowski S: Serum soluble adhesion molecules - sICAM-1, sVCAM-1, sE-selectin - in patients with systemic rheumatoid arthritis. Pol Merkuriusz Lek 17: 353-356, 2004.
30. Palomo I, Marin P, Alarcon M, Gubelin G, Vinambre X, Mora E and Icaza G: Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers. Clin Exp Hypertens 25: 517-523, 2003.
31. Witkowska AM and Borawska MH: Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 15: 91-98, 2004.
32. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG and Tzeng E: Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin-resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol, 2005.
33. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
34. Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A and De Mattia G: Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 44: 431-436, 1995.
35. Ferri C, Bellini C, Desideri G, Baldoncini R, Properzi G, Santucci A and De Mattia G: Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 105 (suppl 2): 38-40, 1997.
36. Hopfner RL and Gopalakrishnan V: Endothelin: emerging role in diabetic vascular complications. Diabetologia 42: 1383-1394, 1999.
37. Krum H, Viskoper RJ, Lacourciere Y, Budde M and Charlon V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338: 784-790, 1998.
38. Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C and Holt DW: Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J 74: 620-624, 1995.
39. Piatti P, Fragasso G, Monti LD, Caumo A, Van Phan C, Valsecchi G, Costa S, Fochesato E, Pozza G, Pontiroli AE and Chierchia S: Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 34: 1452-1460, 1999.
40. Costelli P, Muscaritoli M, Bossola M and Moore-Carrasco R, Crepaldi S, Grieco G, Autelli R, Bonelli G, Pacelli F, Lopez-Soriano FJ, Argiles JM, Doglietto GB, Baccino FM, Rossi Fanelli F: Skeletal muscle wasting in tumor-bearing rats is associated with MyoD down-regulation. Int J Oncol 26: 1663-1668, 2005.
41. Westra J, Kuldo JM, van Rijswijk MH, Molema G and Limburg PC: Chemokine production and E-selectin expression in activated endothelial cells are inhibited by p38 MAPK (mitogen activated protein kinase) inhibitor RWJ 67657. Int Immunopharmacol 5: 1259-1269, 2005.
42. Hemmrich K, Suschek CV, Lerzynski G and Kolb-Bachofen V: iNOS activity is essential for endothelial stress gene expression protecting against oxidative damage. J Appl Physiol 95: 1937-1946, 2003.
43. Li QQ, Bever CT, Burt DR, Judge SI and Trisler GD: Induction of RANTES chemokine expression in human astrocytic cells is dependent upon activation of NF-κB transcription factor. Int J Mol Med 7: 527-533, 2001.
44. Lansbury AJ, Grant PJ and Catto AJ: Atherothrombotic risk factors in subjects with a family history of stroke. Cerebrovasc Dis 14: 153-160, 2002.
45. Pereira J, Soto M, Palomo I, Ocqueteau M, Coetzee LM, Astudillo S, Aranda E and Mezzano D: Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs. Thromb Haemost 87: 905-909, 2002.
46. Moreno PR and Fuster V: New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44: 2293-2300, 2004.
47. Ohkura N, Hiraishi S, Itabe H, Hamuro T, Kamikubo Y, Takano T, Matsuda J and Horie S: Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxyterminal region. Antioxid Redox Signal 6: 705-712, 2004.
48. George JN, Thoi LL, McManus LM and Reimann TA: Isolation of human platelet membrane microparticles from plasma and serum. Blood 60: 834-840, 1982.
49. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE and Sturk A: Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 96: 3534-3541, 1997.
50. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J and Dignat-George F: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 104: 93-102, 1999.
51. Barry OP and FitzGerald GA: Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 82: 794-800, 1999.
52. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA and Nemerson Y: Bloodborne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96: 2311-2315, 1999.
53. Mesri M and Altieri DC: Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 274: 23111-23118, 1999.
54. Barry OP, Pratico D, Savani RC and FitzGerald GA: Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 102: 136-144, 1998.
55. Barry OP, Pratico D, Lawson JA and FitzGerald GA: Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 99: 2118-2127, 1997.
56. Omoto S, Nomura S, Shouzu A, Hayakawa T, Shimizu H, Miyake Y, Yonemoto T, Nishikawa M, Fukuhara S and Inada M: Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 81: 271-277, 1999.
57. Kohler HP and Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342: 1792-1801, 2000.
58. Hamsten A, Wiman B, de Faire U and Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557-1563, 1985.
59. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE and Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341: 1165-1168, 1993.
60. Skurk T and Hauner H: Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 28: 1357-1364, 2004.
61. Muscelli E, Camastra S, Catalano C, Galvan AQ, Ciociaro D, Baldi S and Ferrannini E: Metabolic and cardiovascular assessment in moderate obesity: effect of weight loss. J Clin Endocrinol Metab 82: 2937-2943, 1997.
62. Puccetti L, Sawamura T, Pasqui AL, Pastorelli M, Auteri A and Bruni F: Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 35: 47-51, 2005.
63. Korporaal SJ, Relou IA, van Eck M, Strasser V, Bezemer M, Gorter G, van Berkel TJ, Nimpf J, Akkerman JW and Lenting PJ: Binding of low density lipoprotein to platelet apolipoprotein E receptor 2′ results in phosphorylation of p38MAPK. J Biol Chem 279: 52526-52534, 2004.
64. Chen M, Masaki T and Sawamura T: LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95: 89-100, 2002.
65. Sakurai K and Sawamura T: Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 91: 182-186, 2003.
66. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL and Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92: 3893-3897, 1995.
67. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M and Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85: 1260-1266, 1990.
68. Matsuura E and Lopez LR: Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11: 103-111, 2004.
69. Horkko S, Olee T, Mo L, Branch DW, Woods VL Jr, Palinski W, Chen PP and Witztum JL: Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 103: 941-946, 2001.
70. Amengual O, Atsumi T, Khamashta MA, Tinahones F and Hughes GR: Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 36: 964-968, 1997.
71. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K and Palosuo T: Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91: 23-27, 1995.
72. Klemp P, Cooper RC, Strauss FJ, Jordaan ER, Przybojewski JZ and Nel N: Anti-cardiolipin antibodies in ischaemic heart disease. Clin Exp Immunol 74: 254-257, 1988.
73. Palomo I, Pereira J, Alarcon M, Vasquez M, Pinochet C, Velez MT, Sandoval J, Icaza G and Pierangeli S: Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clin Rheumatol 23: 129-133, 2004.
74. Palomo I, Pereira J, Alarcon M, Larrain AM, Pinochet C, Vasquez M, Velez MT, Leon M, Espinola R and Pierangeli S: Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. J Lab Clin Med 140: 336-341, 2002.
75. Mills JD, Mansfield MW and Grant PJ: Factor XIII-circulating levels and the Val34Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. Thromb Haemost 87: 409-414, 2002.
76. Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA and Zago MA: Factor XIII val34leu and the risk of myocardial infarction. Haematologica 85: 67-71, 2000.
77. Lin CP, Lin WT, Leu HB, Wu TC and Chen JW: Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int J Cardiol 89: 53-62, 2003.
78. Venugopal SK, Devaraj S and Jialal I: Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 14: 33-37, 2005.
79. Kannel WB and McGee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59: 8-13, 1979.
80. Stamler J, Vaccaro O, Neaton JD and Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444, 1993.
81. Caine GJ, Harris AL, Christodoulos K, Lip GY and Blann AD: Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer. Cancer Lett 219: 163-167, 2005.
82. Viles-Gonzalez JF, Anand SX, Zafar MU, Fuster V and Badimon JJ: Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis. J Cardiovasc Pharmacol 43: 669-676, 2004.
83. Samad F, Pandey M and Loskutoff DJ: Regulation of tissue factor gene expression in obesity. Blood 98: 3353-3358, 2001.
84. Samad F, Yamamoto K, Pandey M and Loskutoff DJ: Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med 3: 37-48, 1997.
85. Juhan-Vague I and Alessi MC: PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 78: 656-660, 1997.
86. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T and Miyata T: Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15: 1114-1120, 1995.
87. Licata G, Scaglione R, Avellone G, Ganguzza A, Corrao S, Arnone S and Di Chiara T: Hemostatic function in young subjects with central obesity: relationship with left ventricular function. Metabolism 44: 1417-1421, 1995.
88. Lemieux S: Contribution of visceral obesity to the insulin resistance syndrome. Can J Appl Physiol 26: 273-290, 2001.
89. Garrison RJ, Higgins MW and Kannel WB: Obesity and coronary heart disease. Curr Opin Lipidol 7: 199-202, 1996.
90. Lamon-Fava S, Wilson PW and Schaefer EJ: Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 16: 1509-1515, 1996.
91. Sajadi S, Ezekowitz MD, Dhond A and Netrebko P: Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspect 16: 363-369, 2003.
92. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M and Juhan-Vague I: Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 85: 999-1003, 2001.
93. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E and Schernthaner G: Weight loss reduces tissue factor in morbidly obese patients. Obes Res 11: 950-956, 2003.
94. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE and Wolffenbuttel BH: Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 25: 1340-1345, 2002.
95. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
96. Beckman JA, Creager MA and Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002.
97. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K and Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 97: 2213-2221, 1998.
98. Thompson SG, Kienast J, Pyke SD, Haverkate F and van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332: 635-641, 1995.
99. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M and Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-9, 1987.
100. Meade TW, Ruddock V, Stirling Y, Chakrabarti R and Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342: 1076-1079, 1993.
101. Womack CJ, Ivey FM, Gardner AW and Macko RF: Fibrinolytic response to acute exercise in patients with peripheral arterial disease. Med Sci Sports Exerc 33: 214-219, 2001.
102. Lopes C, Dina C, Durand E and Froguel P: PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 46: 1284-1290, 2003.
103. Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I and Alessi MC: Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 1: 791-797, 2003.
104. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y and Sumida Y: Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 87: 660-665, 2002.